Imatinib Mesylate (Gleevec) Hepatotoxicity

Author： Mindikoglu Ayse   Regev Arie   Bejarano Pablo   Martinez Enrique   Jeffers Lennox   Schiff Eugene  

Publisher： Springer Publishing Company

ISSN： 0163-2116

Source： Digestive Diseases and Sciences, Vol.52, Iss.2, 2007-02, pp. : 598-601

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension

By Chhina Mantej K   Nargues Weir   Grant Geraldine M   Nathan Steven D  

Future Cardiology, Vol. 6, Iss. 1, 2010-01 ,pp. : 19-35

Future Medicine

Access to resources Recommend Favorite

Imatinib Mesylate Does Not Increase Bone Volume In Vivo

By O’Sullivan Susannah  

Calcified Tissue International, Vol. 88, Iss. 1, 2011-01 ,pp. : 16-22

Springer Publishing Company

Access to resources Recommend Favorite

IMATINIB MESYLATE INHIBITS FIBROGENESIS IN ASBESTOS-INDUCED INTERSTITIAL PNEUMONIA

By Vuorinen Kirsi   Gao Fei   Oury Tim D.   Kinnula Vuokko L.   Myllärniemi Marjukka  

Experimental Lung Research, Vol. 33, Iss. 7, 2007-09 ,pp. : 357-373

Informa Healthcare

Access to resources Recommend Favorite

Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate

By Itsukuma Takeyoshi   Ishikawa Hideki   Misawa Mahito   Kai Shunro   Fujimori Yoshihiro   Nakagawa Kazuhiko   Hirota Seiichi   Sugihara Ayako   Terada Nobuyuki   Hara Hiroshi  

Journal of Gastroenterology, Vol. 42, Iss. 5, 2007-05 ,pp. : 402-405

Springer Publishing Company

Access to resources Recommend Favorite

Does Imatinib Mesylate Therapy Cause Growth Hormone Deficiency?

By  

Medical Principles and Practice, Vol. 18, Iss. 5, 2009-07 ,pp. : 360-363

Karger

Access to resources Recommend Favorite